KTT_IDIBAPS

TECNIO Facilitador

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)



D'Investigacions Biomèdiques August Pi i Sunye ∰ ^{Generalitat} de Catalunya tecnio catalonia

ACCIÓ

The Hospital Research Institutes, based on the research activity, generate knowledge and some results that can be taken advantage of by the companies. The TECNIO Facilitador puts you in touch with the spin-offs, the technologies in the licensing phase and the technological capacities of the Research Group.

The Institut d'Investigacions Biomèdiques August Pi i Suny er (IDIBAPS) is the research centre linked to the Hospital Clínic de Barcelona. Founded in 1996, IDIBAPS is structured into 5 research areas, these encompassing 105 groups. With about 1,100 publications a year and an impact factor of more than 6,000 points, IDIBAPS is the main biomedical research centre in Spain.

TECHNOLOGY PORTFOLIO

Technologies. Currently we have a total of 9 licensing opportunities. Some of these technologies are: - Drug eluting stent for the treatment of intimal hyperplasia; - Generation of Hepatic Stellate Cells by direct differentiation of human pluripotent stem cells; - Medical device based on microwave technology for prevention and diagnosis of diseases.

Spin-offs. In the environment of IDIBAPS, 6 spin-offs have been created; for example Transural Biotech and Transplant Biomedical.

MOST RELLEVANT PROJECTS

Licenses. One of the successful cases of our licensed technologies is a patent based on the detection of antibodies generated against the cell adhesion molecule IGLON5, by immunocy tochemistry. The license agreement provides roy alty payments for technology sales. We have just received the first payments.

EBTs. Another successful case is the creation of the spin-off **TRANSPLANT BIOMEDICAL**. The project is led by Dr. Carmen Peralta. Two technologies have been licensed to the IDIBAPS spin-off company: Organ and tissue preservation solution and Medical device for transporting organs to be transplanted

The company has successfully achieved funding with v enture capital funds. The last round of financing took place in December 2016 with an agreement for **2.5 M** € to continue developing its product, the device for the transport of organs.

SOME AVAILABLE TECHNOLOGIES Image: Construction of the particules: Ceria nanoparticles for use in the treatment of hepatocellular carcinoma. Image: Construction of the particules: Ceria nanoparticles for use in the treatment of hepatocellular carcinoma. Image: Construction of the particular carcinoma. Image: Construction of the particular carcinoma. New ELISA test to detect antibodies against citrullinated perides for rheumatoid arthritis diagnosis and prognosis. Image: Construction of the particular carcinoma et echnology for prevention and diagnosis of colorectal cancer. Manufacturing

Adress C/Rosselló 149-153

08036 Barcelona Barcelonès Contact person

Elisenda Vendrell elisenda.vendrell@idibaps.org 932279165

Director

Ramón Gomis

Surface incubation spaces in m2

Staff

5

www.idibaps.org